PURPOSE: Recent studies have identified polycomb-group gene Bmi-1 as oncogene in the generation of mouse pre-cell lymphomas, and overexpression of Bmi-1 has been found in several human tumor with the disease progress and poor prognosis of the cancer patients. METHODS: In present study, we investigated Bmi-1 expression and its prognostic significance in hepatocellular carcinoma (HCC) by performing immunohistochemical analysis, using a total of 137 HCC clinical tissue samples. RESULTS: High Bmi-1 expression (Bmi-1 2+ or 3+) was shown in 29.9% cases. The positive immuno-staining of Bmi-1 was not only in well/moderately-differentiated tumor cells, but also in surrounding noncancerous or cirrhotic liver tissue. Bmi-1 expression level did not correlate with any clinicopathological parameters. However, survival analysis showed that the high-Bmi-1 group had a significantly shorter overall survival time than the low-Bmi-1 group (P=0.047). Multivariate analysis after 24 months revealed that Bmi-1 expression was a significant and independent prognostic parameter (P=0.002) for HCC patients. CONCLUSIONS: Our study indicated that Bmi-1 could be a candidate biomarker for long-term survival in HCC.
PURPOSE: Recent studies have identified polycomb-group gene Bmi-1 as oncogene in the generation of mouse pre-cell lymphomas, and overexpression of Bmi-1 has been found in several humantumor with the disease progress and poor prognosis of the cancerpatients. METHODS: In present study, we investigated Bmi-1 expression and its prognostic significance in hepatocellular carcinoma (HCC) by performing immunohistochemical analysis, using a total of 137 HCC clinical tissue samples. RESULTS: High Bmi-1 expression (Bmi-1 2+ or 3+) was shown in 29.9% cases. The positive immuno-staining of Bmi-1 was not only in well/moderately-differentiated tumor cells, but also in surrounding noncancerous or cirrhotic liver tissue. Bmi-1 expression level did not correlate with any clinicopathological parameters. However, survival analysis showed that the high-Bmi-1 group had a significantly shorter overall survival time than the low-Bmi-1 group (P=0.047). Multivariate analysis after 24 months revealed that Bmi-1 expression was a significant and independent prognostic parameter (P=0.002) for HCC patients. CONCLUSIONS: Our study indicated that Bmi-1 could be a candidate biomarker for long-term survival in HCC.
Authors: M K Kang; R H Kim; S J Kim; F K Yip; K-H Shin; G P Dimri; R Christensen; T Han; N-H Park Journal: Br J Cancer Date: 2006-12-19 Impact factor: 7.640
Authors: S Vonlanthen; J Heighway; H J Altermatt; M Gugger; A Kappeler; M M Borner; M van Lohuizen; D C Betticher Journal: Br J Cancer Date: 2001-05-18 Impact factor: 7.640
Authors: J C Steele; E E Torr; K L Noakes; E Kalk; P A Moss; G M Reynolds; S G Hubscher; M van Lohuizen; D H Adams; L S Young Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640
Authors: Aaron Cooper; John van Doorninck; Lingyun Ji; Darren Russell; Marc Ladanyi; Hiroyuki Shimada; Mark Krailo; Richard B Womer; Jessie Hao-ru Hsu; Dafydd Thomas; Timothy J Triche; Richard Sposto; Elizabeth R Lawlor Journal: Clin Cancer Res Date: 2010-11-03 Impact factor: 12.531
Authors: Monica Bartucci; Mohamed S Hussein; Eric Huselid; Kathleen Flaherty; Michele Patrizii; Saurabh V Laddha; Cindy Kui; Rachel A Bigos; John A Gilleran; Mervat M S El Ansary; Mona A M Awad; S David Kimball; David J Augeri; Hatem E Sabaawy Journal: Target Oncol Date: 2017-08 Impact factor: 4.493
Authors: V Häyry; L K Mäkinen; T Atula; H Sariola; A Mäkitie; I Leivo; H Keski-Säntti; J Lundin; C Haglund; J Hagström Journal: Br J Cancer Date: 2010-02-09 Impact factor: 7.640